Johnson & Johnson
JNJ: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$486.00 | Ynsd | Jjvnkbbs |
Johnson & Johnson: Ambrx Acquisition Expands Potential in Antibody Drug Conjugates
Johnson & Johnson’s announced $2 billion acquisition of Ambrx Biopharma yields new antibody drug conjugate technology. While we don’t believe the deal will affect our fair value estimate or wide moat rating, it does increase J&J's potential in the increasingly important ADC landscape.